Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms 2Osteoporosis 2Neoplasms, Plasma Cell 1Multiple Myeloma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

aldesleukin 23Bevacizumab 17Magnetic Resonance Spectroscopy 15Specimen Handling 12Sunitinib 11Sorafenib 11Interferon-alpha 11cabozantinib 9Cyclophosphamide 9Nivolumab 8Immunoglobulin G 7Disulfides 7temsirolimus 6fludarabine phosphate 5Sirolimus 5Introns 5Fluorouracil 5Erlotinib Hydrochloride 5Chemotherapy, Adjuvant 5sargramostim 4cediranib 4bryostatin 1 4Vorinostat 4Neoadjuvant Therapy 4Ipilimumab 4Interleukin-2 4Interferon alpha-2 4Biopsy 4vandetanib 3ixabepilone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Renal Cell × Zoledronic Acid × Clear all
NCT00588913 2013-07-10

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases

National Cancer Institute (NCI)

Phase 1/2 Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡